Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OTS-102
- Development stage
- Unknown
- Lead developer
- Oncotherapy Science
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
OTS-102 is an HLA-A*24:02-restricted peptide vaccine that targets Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), also known as KDR. Developed by OncoTherapy Science, the vaccine is designed to stimulate the production of specific cytotoxic T lymphocytes (CTLs) that recognize and destroy VEGFR2-expressing endothelial cells in the tumor neovasculature. This mechanism aims to inhibit tumor angiogenesis and suppress tumor growth. OTS-102 is primarily being investigated for the treatment of progressive vestibular schwannoma in patients with neurofibromatosis type 2 (NF2)-related schwannomatosis, often in combination with OCV-101, a VEGFR1-targeting peptide vaccine.
- Other names
- VEGFR2 peptide vaccineVEGFR-2 peptide vaccineVEGFR 2 peptide vaccine
02
Targets
VEGFR2-pMHC (Vascular endothelial growth factor receptor 2-derived peptide epitope presented on MHC class I)
Beyond the preview
Go deeper on OTS-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OTS-102.